AIMS & SCOPE
Letters in Drug Design & Discovery publishes letters, full-length/mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery. To learn more about the journal, please visit: https://benthamscience.com/journals/letters-in-drug-design-and-discovery/
Author(s): Maryam Norouzbahari, Emine V. Burgaz, Tugba Ercetin, Amirhossein Fallah, Alireza Foroumadi, Loghman Firoozpour, Mustafa F. Sahin, Mustafa Gazi, Hayrettin O. Gulcan*.
Journal Name: Letters in Drug Design & Discovery
Considering the limitations of current cholinesterase inhibitor drugs for the treatment of Alzheimer’s disease, there is ongoing research activities to find out alternative drug candidates. The aryl-spacer-N-benzyl pharmacophore model has been effectively utilized to design various types of cholinesterase inhibitor molecules, including donepezil. Within this research study, we have questioned the significance of the benzyl group within this pharmacophore employing the urolithin derivatives. Urolithins are benzo[c]chromene analogue metabolites of ellagitannins, abundantly found in pomegranate and berry fruits. Read out full article here: http://www.eurekaselect.com/159057
Author(s): Min Zou, Bo Jin, Yanrong Liu, Huiping Chen, Zhuangli Zhang, Changzheng Zhang, Zhihong Zhao, Liyun Zheng*.
Journal Name: Letters in Drug Design & Discovery
With the approval of gefitinib, erlotinib, afatinib, and osimertinib for clinical use, targeting Epidermal Growth Factor Receptor (EGFR) has been intensively pursued. Similar to most therapies, challenges related to the treatment resistance against these drugs have emerged over time, so new EGFR Tyrosine Kinase Inhibitors (TKIs) need to be developed. This study aimed to investigate the potential use of a series of thiophene-bearing quinazoline derivatives as EGFR inhibitors. We designed and synthesized nine quinazolin derivatives, among which five compounds (5e, 5f, 5g, 5h, and 5i) were reported for the first time. Read out full article here: http://www.eurekaselect.com/164334
Chronic Kidney disease (CKD) is highly associated with all-cause mortality, Diabetic Nephropathy (DN), cardiovascular events and hospitalization whether the patient has an existing risk or current cardiovascular disease or not. CKD can increase the chances of cardiovascular disease by two to fifty times and 50% mortality of patients with end stage renal disease (ESRD) on dialysis attributed to CVD and its complications. In this review, Co-enzyme Q10 (CoQ10) was tested as a potential treatment for CKD. The systemic review and meta-analysis of randomized control trials (RCTs) was conducted to evaluate the effects of CoQ10 supplementation on metabolic profiles of patients diagnosed with CKD.
CoQ10 is a potent lipophilic antioxidant that couple’s electron transport to oxidative phosphorylation in mitochondria. It is generally used as an alternative and complementary therapy for diseases with metabolic disorders. The supplementary protein has shown beneficial effects during the treatment of heart failure. It was found that the circulating concentration in patients with CKD had been decreased. This suggested that the CoQ10 antioxidant treatment would be an ideal solution for the disease. The results accumulated during meta-analysis proved that the CoQ10 supplementation significantly reduced total-cholesterol, malondialdehyde, and creatinine levels in patients diagnosed with CKD. It did not affect Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2018-12/bsp-cqs122718.php
Prof. Ben M. Dunn
Editor in Chief: Current Protein & Peptide Science
Department of Biochemistry and Molecular Biology University of Florida
College of Medicine, P.O. Box 100245, Gainesville
Florida, FL 32610-0245
Fourth Military Medical University is a military institution of higher learning, affiliated to the People’s Liberation Army of the People’s Republic of China. It was formed by the merger of former Fourth Military Medical University (First Military Medical College) and Fifth Military Medical University (Third Military Medical College ). The predecessor of Fifth Military Medical University is the “Medicine School of National Central University”, which was the best medicine school in China, founded in Nanjing in 1935. It was renamed the “Medicine School of Nanjing University” in 1949, and renamed “Eastern Military Medical College” and then “Third Military Medical College” and “Fifth Military Medical University” in 1952. The “People’s Medical College of Northwestern Military Region”, the predecessor of former Fourth Military Medical University was founded in 1941, relocated in Xi’an in 1948, and renamed “Northwestern Military Medical College” and then “First Military Medical College” and “Fourth Military Medical University” in 1952. The two medical universities were merged to form the new Fourth Military Medical University affiliated to PLA in 1954 in Xi’an, the capital of Shaanxi Province, China. It is a Chinese Ministry of Education Double First Class Discipline University, with Double First Class status in certain disciplines.
Central Institute of Medicinal and Aromatic Plants (CIMAP) is a research institute of Council of Scientific and Industrial Research (CSIR) with its headquarter in Lucknow. It is engaged in the field of science and business of medicinal and aromatic plants. CIMAP has four research centers situated in Bangalore, Hyderabad, Pantnagar and Purara (near Bageshwar, Uttarakhand).The branch in Hyderabad was established on 7 July 1982.
Hebei University of Technology (HEBUT) is a key provincial university as well as one of the national universities under “Project 211”. It is also an important university under the authority of Hebei province which specializes in engineering studies and combines multiple academic areas including technology, science, economics, management and arts . It was founded in 1903, and was originally known as Beiyang Technical School.
HEBUT has 69 undergraduate programs, embracing a wide range of disciplines including engineering, science, economics, management, art and law. It is composed of 17 schools/departments, 1 physical-training teaching department and 2 teaching administrative schools. It has 6 state-level disciplines with specific characteristics and 18 province-level representative programs, 2 national key disciplines, 4 province-level advantageous disciplines and 20 provincial key disciplines. There are 42 disciplines authorized to award doctor degrees, 131 disciplines authorized to offer master’s degrees or professional degree fields. HEBUT is the first engineering-based university to launch MBA program in China. Meanwhile, it is the only university in Hebei province that offers an EMBA education. It possesses 9 post doctoral work stations, among which “Material Science and Engineering” is special national program.
HEBUT owns 2474 qualified faculty members. Among 1365 full-time teachers, 706 hold senior professional titles, and 682 have doctorate degrees. With a “Long River” scholar and a “1000 Plan” professor, HEBUT further ensures that HEBUT students receive optimal instruction in their chosen field. There is an outstanding team of national technology expertise, 3 state-level teaching teams, 2 innovative research teams with the Ministry of Education, a state-level top teacher as well as 5 provincial teaching teams. 187 staff members won provincial and ministerial level honors, including the “National Middle-aged and Young Experts with Outstanding Contributions”, and national candidates in the “New Century Talents Project”. Hundreds of staff members hold posts of chairman, vice-chairman and secretary-general in professional societies or associations at or above provincial level.
HEBUT is equipped with 1 national engineering research center and 17 provincial and ministerial level research institutes, including 1 state key laboratory base co-founded by Hebei province and the Ministry of Science and Technology and the Engineering Research Center of the Ministry of Education.
HEBUT is located in Tianjin. and also has campuses in Langfang city. HEBUT covers an area of more than 267 hectares with a construction group area of 870,000 square meters. In the 200-hectare Beichen campus, a 400,000-square-meter construction project has been completed and put into use where, at present, there are more than 21,000 full-time students, including 6,373 post-graduates. The City College which is sponsored by HEBUT has 16,000 students, with 16,000 more pursuing their vocational and bachelor’s degrees through adult education. The school teaching and research equipment is worth 372 million RMB, and there are 1.88 million books in the school library. Apart from that, well-equipped stadiums, dormitories and canteens facilitate student campus life.
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Abstracted and Indexed in:
- Science Citation Index®
- Journal Citation Reports/Science Edition
- Science Citation Index Expanded
- Index to Scientific Reviews®
- Biochemistry and Biophysics Citation Index®
- Current Contents® – Life Sciences
- Research Alert
- BIOSIS Previews
- BIOSIS Reviews Reports and Meetings
- Prous Science Integrity®
- MEDLINE/PubMed/Index Medicus
- EMBASE/Excerpta Medica
- Chemical Abstracts Service/SciFinder
- Google Scholar
- Reference Update
- Index Copernicus
- MediaFinder®-Standard Periodical Directory
- Genamics JournalSeek
- CNKI Scholar
- Suweco CZ
- TOC Premier
- British Library
- Ulrich’s Periodicals Directory
The Journal “Current Medicinal Chemistry” is interested in appointing active Reviewers on the Journal’s Board. If you are working in the field mentioned and are interested in becoming an Reviewer, send your CV and a list of publications at the below mentioned email. If the scope of the journal is not directly related to your field of interest then please feel free to recommend suitable colleagues for the Reviewer of the journal and send us their CV and a list of publications, if possible.
Submit your CV at your earliest convenience at firstname.lastname@example.org and CC email@example.com, mentioning in the subject line your field of interest. The responsibilities of Reviewer will be discussed in detail further once the CV is received.